Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionSubcutaneous formulation of small interfering RNA (siRNA) against angiopoietin-like 3 (ANGPTL3)
Molecular Target Angiopoietin-like 3 (ANGPTL3)
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: siRNA
Latest Stage of DevelopmentPreclinical
Standard IndicationHyperlipidemia
Indication DetailsTreat genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today